Prof Silvia Novello speaks to ecancer about the international tailored chemotherapy adjuvant trial (ITACA)’s final results.
She initially explains that this is an ongoing phase III multicentre randomised trial comparing adjuvant pharmacogenomic-driven chemotherapy, based on thymidilate synthase (TS) and excision-repair cross-complementing -1 (ERCC1) gene expression versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small cell lung cancer. She then mentions the methodology of this study.
Prof Novello whilst explaining the results says that although the main evaluated end-points did not reach statistical significance, there are still other observations that can be derived form this trial and can be used in future in trials.
Concluding, she talks about how the results from this trial can help in the future trial design.